TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22507080

Group type: EXPERIMENTAL
Intervention: FACTS diabetes education programme (six 90‐min monthly sessions attended by parents and adolescents)
Number of subjects: 305

Group type: COMPARATOR
Intervention: Conventional clinical care
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: FACTS diabetes education programme
Number of subjects: 305
Study: 20409509

Group type: EXPERIMENTAL
Intervention: Altered surgical technique (ligation of lymph vessels, suturing latissimus dorsi to chest wall, fixing skin flap to muscle)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Conventional surgical technique
Number of subjects: 201
Study: 18599105

Group type: EXPERIMENTAL
Intervention: Photographs rotated to varying extents within a constant square frame
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Photographs viewed in interiors and during recognition of previously seen pictures
Number of subjects: 0
Study: 16019281

Group type: EXPERIMENTAL
Intervention: Walking group (n=15)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Hand/face exercises group (n=13)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (n=15)
Number of subjects: 43
Study: 12240905

Group type: EXPERIMENTAL
Intervention: Intensive Insulin Therapy (IIT)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Conventional Insulin Therapy (CIT)
Number of subjects: 46
Study: 10356917

Group type: EXPERIMENTAL
Intervention: Cortexin delivered via nasal electrophoresis (NE) in combination with standard therapy
Number of subjects: 76

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 76
Study: 8522381

Group type: COMPARATOR
Intervention: Ofloxacin 400 mg once daily
Number of subjects: 474

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 200 mg twice daily
Number of subjects: 474
Study: 2021151

Group type: EXPERIMENTAL
Intervention: Total cholesterol > 6 mmol/liter
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: LDL cholesterol > 3.5 mmol/liter
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: HDL cholesterol > 1.2 mmol/liter
Number of subjects: 346
Study: 6460472

Group type: EXPERIMENTAL
Intervention: Minocycline 200 mg
Number of subjects: 15

Group type: COMPARATOR
Intervention: Tetracycline 1,000 mg
Number of subjects: 15
Study: 30977077

Group type: EXPERIMENTAL
Intervention: PEG‐S2 (simethicone addition in the evening of the day prior to colonoscopy)
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: PEG‐S1 (simethicone addition in the morning on the day of colonoscopy)
Number of subjects: 234

Group type: COMPARATOR
Intervention: Control (PEG‐Asc only)
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: PEG‐S2
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: PEG‐S1
Number of subjects: 234

Group type: COMPARATOR
Intervention: Control
Number of subjects: 234
Study: 28709045

Group type: EXPERIMENTAL
Intervention: Perceived larger hole (Ebbinghaus illusion with small circles)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Perceived smaller hole (Ebbinghaus illusion with large circles)
Number of subjects: 20
Study: 24983687

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (PFMT)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Control group (no PFMT)
Number of subjects: 175
Study: 23608797

Group type: EXPERIMENTAL
Intervention: Enteral nutrition fluid (30 ml·kg(‐1)·d(‐1))
Number of subjects: 120

Group type: COMPARATOR
Intervention: Traditional intestinal preparation (fasting, oral antibiotic, cleaning enema)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Enteral nutrition
Number of subjects: 120

Group type: COMPARATOR
Intervention: Traditional bowel preparation
Number of subjects: 120
Study: 21389858

Group type: EXPERIMENTAL
Intervention: 1 g of oral flucloxacillin
Number of subjects: 70

Group type: COMPARATOR
Intervention: Identical placebo
Number of subjects: 70
Study: 19637415

Group type: EXPERIMENTAL
Intervention: Atazanavir and ritonavir combination
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fixed-dose combination of lopinavir and ritonavir
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atazanavir
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ritonavir
Number of subjects: 0
Study: 17670729

Group type: EXPERIMENTAL
Intervention: Orientation A of bi-leaflet prosthesis (hinge mechanism perpendicular to a line drawn between the coronary ostia)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Orientation B of bi-leaflet prosthesis (hinge mechanism parallel to the line between the ostia)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Bio-prosthesis
Number of subjects: 21
Study: 15301651

Group type: EXPERIMENTAL
Intervention: Couple communication about cancer-related issues
Number of subjects: 148

Group type: COMPARATOR
Intervention: Couple communication about general issues
Number of subjects: 148
Study: 11503782

Group type: COMPARATOR
Intervention: Abciximab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Abciximab started 24 hours before angioplasty
Number of subjects: 0
Study: 9315593

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 0
Study: 8397246

Group type: EXPERIMENTAL
Intervention: Verapamil + Low-salt diet
Number of subjects: 418

Group type: COMPARATOR
Intervention: Verapamil + High-salt diet
Number of subjects: 418
Study: 3526885

Group type: EXPERIMENTAL
Intervention: Aztreonam/vancomycin
Number of subjects: 535

Group type: EXPERIMENTAL
Intervention: Aztreonam/vancomycin/amikacin
Number of subjects: 535

Group type: COMPARATOR
Intervention: Moxalactam/ticarcillin
Number of subjects: 535

Group type: EXPERIMENTAL
Intervention: Aztreonam
Number of subjects: 535
Study: 30099555

Group type: EXPERIMENTAL
Intervention: House of Quality for Behavioral Science tool
Number of subjects: 0
Study: 29409920

Group type: EXPERIMENTAL
Intervention: Citalopram (10 mg)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 27298549

Group type: EXPERIMENTAL
Intervention: Stainless steel staples
Number of subjects: 80

Group type: COMPARATOR
Intervention: 3‐0 silk sutures
Number of subjects: 80
Study: 24906705

Group type: EXPERIMENTAL
Intervention: ADSE protocol (atropine first, 1.0 mg administered 3 min before dobutamine infusion)
Number of subjects: 100

Group type: COMPARATOR
Intervention: DASE protocol (conventional atropine administration)
Number of subjects: 100
Study: 21221681

Group type: EXPERIMENTAL
Intervention: Opalescence 10% PF™ (OPL)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Vivastyle® 10%™ (VS10%)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Vivadent Paint On Plus™ (PO+)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Trés White Supreme™ (TWS)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study: 20135933

Group type: EXPERIMENTAL
Intervention: Cyanoacrylate sealant (FloraSeal)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Povidone-iodine (Betadine)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combined Povidone-iodine and cyanoacrylate
Number of subjects: 60
Study: 18589451

Group type: EXPERIMENTAL
Intervention: Early and higher intravenous amino acid (EHAA) supplementation (2 g x kg(‐1) x d(‐1) advanced by 1 g x kg(‐1) daily to 4 g x kg(‐1) x d(‐1))
Number of subjects: 62

Group type: COMPARATOR
Intervention: Standard intravenous amino acid (SAA) supplementation (starting at 0.5 g x kg(‐1) x d(‐1) increased by 0.5 g x kg(‐1) daily to a maximum of 3 g x kg(‐1) x d(‐1))
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: EHAA supplementation
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: AA infusion
Number of subjects: 62
Study: 16385905

Group type: EXPERIMENTAL
Intervention: Pearson correlation coefficient (γ = 1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Kendall correlation coefficient (γ = 0)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Correlation coefficient (γ = 0.5)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: General class of sample correlation coefficients
Number of subjects: 0
Study: 22123096

Group type: EXPERIMENTAL
Intervention: Oral 9-THC 10 mg QID
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oral 9-THC 20 mg QID
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oral 9-THC maintenance
Number of subjects: 12
Study: 12019584

Group type: EXPERIMENTAL
Intervention: Ankle-foot orthosis (AFO)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No AFO (control condition)
Number of subjects: 0
Study: 9850410

Group type: EXPERIMENTAL
Intervention: Tetracycline
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Ampicillin
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Erythromycin
Number of subjects: 184

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 184
Study: 7505877

Group type: EXPERIMENTAL
Intervention: Epirubicin, vinblastine, bleomycin, and dacarbazine (EVBD)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Mitoxantrone, vinblastine, bleomycin, and dacarbazine (MVBD)
Number of subjects: 70
Study: 2642499

Group type: EXPERIMENTAL
Intervention: Oral physostigmine
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 4357222

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30360210

Group type: COMPARATOR
Intervention: Conventional orthodontic composite resin (Transbond XT)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: NP1 (1% YF3 nanoparticles)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: NP2 (2% YF3 nanoparticles)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: NP3 (3% YF3 nanoparticles)
Number of subjects: 60
Study: 28592584

Group type: EXPERIMENTAL
Intervention: ACP video intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control video (informational video about the hospital surgical programme)
Number of subjects: 0
Study: 24661235

Group type: EXPERIMENTAL
Intervention: 1.8 mL of 4% articaine with 1 : 100 000 epinephrine
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: 3.6 mL of 4% articaine with 1 : 100 000 epinephrine
Number of subjects: 234

Group type: COMPARATOR
Intervention: 1.8 mL of 4% articaine with 1 : 100 000 epinephrine (initial IANB)
Number of subjects: 234
Study: 22361894

Group type: EXPERIMENTAL
Intervention: Problem-Based Learning (PBL)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Traditional method with study skills instruction
Number of subjects: 39

Group type: COMPARATOR
Intervention: Traditional method without study skills instruction
Number of subjects: 39
Study: 22123795

Group type: EXPERIMENTAL
Intervention: Longitudinal care (LC) - 1 year of telephone-based chronic disease management with continued counseling and nicotine replacement therapy for an additional 48 weeks.
Number of subjects: 443

Group type: COMPARATOR
Intervention: Usual care (UC) - 8 weeks of evidence-based treatment with 2 additional counseling calls.
Number of subjects: 443

Group type: EXPERIMENTAL
Intervention: Longitudinal care (LC) - compared to UC, LC participants received more counseling calls (mean, 16.5 vs 5.8 calls; P < .001), longer total duration of counseling (283 vs 117 minutes; P < .001), and more nicotine replacement therapy (4.7 vs 2.4 boxes of patches; P < .001).
Number of subjects: 443

Group type: EXPERIMENTAL
Intervention: Longitudinal care (LC) - adjusted odds ratio for prolonged abstinence at 18 months was 1.74 (95% CI, 1.08‐2.80).
Number of subjects: 443

Group type: EXPERIMENTAL
Intervention: Longitudinal care (LC) - participants who did not quit reduced smoking more than UC participants (significant only at 12 months).
Number of subjects: 443
Study: 19595103

Group type: EXPERIMENTAL
Intervention: Microendoscopic discectomy (MED)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Percutaneous lumbar discectomy (PLD)
Number of subjects: 186
Study: 17203621

Group type: EXPERIMENTAL
Intervention: Antidepressants for treatment of Post Stroke Depression (PSD)
Number of subjects: 0
Study: 12949684

Group type: EXPERIMENTAL
Intervention: Impaza (antibodies to endothelial NO synthase in ultralow doses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 0
Study: 11004016

Group type: EXPERIMENTAL
Intervention: L-arginine (30 g over 30 min)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Growth hormone-releasing peptide-2 (1 microg/kg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Combination of L-arginine and growth hormone-releasing peptide-2
Number of subjects: 18

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 18
Study: 9315992

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 339

Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 339
Study: 8384435

Group type: EXPERIMENTAL
Intervention: Hand-sutured ileoanal anastomosis (group 1)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Double-stapled ileoanal anastomosis (group 2)
Number of subjects: 40
Study: 31678060

Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy (PBMT) with 940nm, 2.5W, 120s, 85.71J/cm2, 0.89W/cm2, three times per week for two weeks (G1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy (PBMT) with 940nm, 4.1W, 120s, 68.33J/cm2, 0.58W/cm2, three times per week for two weeks (G2)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group receiving sodium naproxen 250mg every 8 hours for 6 days (CG)
Number of subjects: 60
Study: 30643959

Group type: EXPERIMENTAL
Intervention: Traditional high-intensity interval training (TRAD)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Periodized high-intensity interval training (PER)
Number of subjects: 17
Study: 29068288

Group type: EXPERIMENTAL
Intervention: Early surgical treatment
Number of subjects: 29

Group type: COMPARATOR
Intervention: Delayed surgical treatment
Number of subjects: 29
Study: 25190072

Group type: EXPERIMENTAL
Intervention: Intensive statin therapy
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Baseline lipid-rich plaque (LRP)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Large plaque burden with large LRP at baseline
Number of subjects: 66
Study: 23241723

Group type: EXPERIMENTAL
Intervention: Adductor Canal Block (ACB)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Femoral Nerve Block (FNB)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 21597387

Group type: EXPERIMENTAL
Intervention: Linifanib 0.10 mg/kg (low dose)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Linifanib 0.25 mg/kg (high dose)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Linifanib (both doses)
Number of subjects: 139
Study: 19812066

Group type: EXPERIMENTAL
Intervention: Intra-partum single-dose nevirapine
Number of subjects: 330
Study: 16901024

Group type: EXPERIMENTAL
Intervention: Botulinum toxin injection into the musculature adjacent to the wound
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo injection into the musculature adjacent to the wound
Number of subjects: 31
Study: 15293866

Group type: EXPERIMENTAL
Intervention: Solifenacin 10 mg (oral)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Solifenacin 5 mg (intravenous)
Number of subjects: 12
Study: 11166784

Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg daily for 6 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 30
Study: 15321243

Group type: EXPERIMENTAL
Intervention: 1.5% lidocaine with epinephrine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 3% chloroprocaine with sodium bicarbonate
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (elective cesarean section)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Chloroprocaine
Number of subjects: 30
Study: 8165845

Group type: EXPERIMENTAL
Intervention: Iomeprol 400
Number of subjects: 50

Group type: COMPARATOR
Intervention: Natrium-meglumine-diatrizoate (Urografin 76)
Number of subjects: 50
Study: 2974714

Group type: EXPERIMENTAL
Intervention: Atracurium
Number of subjects: 3381

Group type: COMPARATOR
Intervention: Alcuronium
Number of subjects: 3381

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 3381
Study: 31996422

Group type: EXPERIMENTAL
Intervention: HIV envelope vaccination (subtype C, DNA/MVA, phase 1 trial, n=1)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: HIV envelope vaccination (subtype C, DNA/MVA/gp140 protein, phase 1 trial, n=2)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: HIV envelope vaccination (multisubtype, DNA/adenovirus serotype 5 [Ad5], phase 2 trial, n=7)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo recipients (n=4)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: HIV envelope vaccination (all groups combined)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Unvaccinated controls (HIV-infected South African individuals)
Number of subjects: 18
Study: 30005748

Group type: EXPERIMENTAL
Intervention: Level overlap and color coding
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of level overlap and color coding
Number of subjects: 0

Group type: COMPARATOR
Intervention: Base-case study arm without level overlap or color coding
Number of subjects: 0
Study: 27327078

Group type: EXPERIMENTAL
Intervention: Lambda/RBV/DCV
Number of subjects: 440

Group type: COMPARATOR
Intervention: Alfa/RBV/TVR
Number of subjects: 440
Study: 25551592

Group type: EXPERIMENTAL
Intervention: 10% lidocaine spray
Number of subjects: 214

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 214
Study: 22957727

Group type: EXPERIMENTAL
Intervention: Atorvastatin treatment
Number of subjects: 16

Group type: COMPARATOR
Intervention: Validation group (healthy volunteers)
Number of subjects: 16
Study: 20496728

Group type: EXPERIMENTAL
Intervention: Acupoint catgut implantation
Number of subjects: 65

Group type: COMPARATOR
Intervention: Medication (2 pills of Fu fuchun capsule, once a day)
Number of subjects: 65
Study: 19006920

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 17186726

Group type: EXPERIMENTAL
Intervention: Drug cupping therapy (DCT) with Liuwei Dihuang Pill (LDP)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Common cupping therapy without drug
Number of subjects: 77
Study: 12589012

Group type: EXPERIMENTAL
Intervention: Computer-based decision support system (CDSS) providing patient-specific information
Number of subjects: 1952

Group type: COMPARATOR
Intervention: Control (routine practice observed)
Number of subjects: 1952
Study: 10907147

Group type: EXPERIMENTAL
Intervention: Therapists' systemic responses measured using a newly developed scale.
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Exploratory analysis of 11 clients excluding overriding factors.
Number of subjects: 15
Study: 8853770

Group type: EXPERIMENTAL
Intervention: Omeprazole dual therapy (omeprazole 40 mg o.m. + amoxycillin 500 mg t.d.s.)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Omeprazole triple therapy (omeprazole 40 mg o.m. + amoxycillin 500 mg t.d.s. + metronidazole 400 mg t.d.s.)
Number of subjects: 105

Group type: COMPARATOR
Intervention: H. pylori negative patients
Number of subjects: 105

Group type: COMPARATOR
Intervention: H. pylori positive patients
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 105
Study: 1289921

Group type: EXPERIMENTAL
Intervention: Intramuscular desipramine (DMI) 75 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 6549160

Group type: EXPERIMENTAL
Intervention: Allopurinol (20 mg/kg/day orally for 3 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 31883766

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.1 mcg/kg/hour) administered during anesthesia and through postoperative day 2
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.9% saline administered at the same rate for the same duration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 0
Study: 30902424

Group type: EXPERIMENTAL
Intervention: HF-POMS tool
Number of subjects: 341
Study: 29270001

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 52

Group type: COMPARATOR
Intervention: Atorvastatin 20 mg (Control)
Number of subjects: 52
Study: 25668196

Group type: EXPERIMENTAL
Intervention: 30 minute morning and afternoon naps
Number of subjects: 11

Group type: COMPARATOR
Intervention: No naps
Number of subjects: 11
Study: 24667750

Group type: EXPERIMENTAL
Intervention: Higher vegetable consumption (doubling the serving sizes of vegetables)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard healthy diet advice (control group)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Higher vegetable consumption
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Both groups (higher vegetable consumption and control)
Number of subjects: 120
Study: 21664603

Group type: EXPERIMENTAL
Intervention: Prismatic glasses and optometric correction
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 45
Study: 19678557

Group type: EXPERIMENTAL
Intervention: Spiritual-hypnosis assisted therapy (SHAT)
Number of subjects: 226

Group type: COMPARATOR
Intervention: No therapy (control group)
Number of subjects: 226
Study: 17446521

Group type: EXPERIMENTAL
Intervention: Original protocol
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Modified protocol
Number of subjects: 160
Study: 15213473

Group type: EXPERIMENTAL
Intervention: Rocker sole
Number of subjects: 10

Group type: COMPARATOR
Intervention: Shoes without rocker soles
Number of subjects: 10
Study: 11280344

Group type: EXPERIMENTAL
Intervention: UCS inflation
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: UCS deflation
Number of subjects: 30
Study: 9260120

Group type: EXPERIMENTAL
Intervention: Vacuum with M-cup
Number of subjects: 637

Group type: COMPARATOR
Intervention: Forceps
Number of subjects: 637
Study: 8297714

Group type: EXPERIMENTAL
Intervention: Enhanced educational intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Informational educational intervention
Number of subjects: 0
Study: 3326567

Group type: EXPERIMENTAL
Intervention: Iodophor-impregnated plastic incise drape
Number of subjects: 1102

Group type: COMPARATOR
Intervention: Standard skin preparation technique (Control)
Number of subjects: 1102
Study: 31560227

Group type: EXPERIMENTAL
Intervention: Bulking laxative and probiotic
Number of subjects: 17

Group type: COMPARATOR
Intervention: Osmotic laxative
Number of subjects: 17
Study: 29486364

Group type: EXPERIMENTAL
Intervention: Symptomatic unilateral gluteal tendinopathy (GT)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Symptomatic unilateral hip osteoarthritis (HOA)
Number of subjects: 133